E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Cushing s Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone ACTH Secretion |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10014146 |
E.1.2 | Term | Ectopic ACTH syndrome |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to demonstrate that daily administration of mifepristone in subjects with Cushing s syndrome Caused by ectopic ACTH secretion will improve the glucocorticoid-dependent parameters of blood pressure and/or glucose tolerance. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are to assess the impact of long-term administration of mifepristone on other glucocorticoid-dependent parameters, and the safety of the agent. The clinical and biochemical features and safety parameters which will be evaluated are detailed in protocol. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
Subjects will be included if they have ALL of the three following criteria 1. Hypercortisolism from Cushing s syndrome caused by ectopic ACTH secretion confirmed by - Inferior petrosal sinus sampling IPSS with a central to peripheral ACTH ratio of less than 2.0 before CRH administration and less than 3.0 after CRH administration. - or biopsy with ACTH immunoreactivity. - or presence of a tumor evidenced by imaging combined with both a negative CRH test and a negative 8 mg dexamethasone suppression test. No major change in tumor status/anti-tumor therapy should be expected during the study AND 2. Glucose intolerance AND/OR hypertension that is considered to be caused or worsened by the hypercortisolism - Diabetes defined by fasting plasma glucose level greater than or equal to 7.0 mmol/l 126 mg/dl or 2-hour glucose plasma level after 75 g OGTT greater than or equal to 11.1 mmol/l 200 mg/dl or treated diabetes or glucose intolerance defined by fasting plasma glucose values between 5.5 mmol/l 100 mg/dl and 7.0 mmol/l 126 mg/dl or 2-hour glucose plasma level after 75 g OGTT greater than or equal to 7.8 mmol/l 140 mg/dl and 11.1 mmol/l 200 mg/dl Prior to study entry, fasting blood sugar must be less than 11.1 mmol/l 200 mg/dl for at least two weeks - Hypertension defined by systolic BP greater than or equal to 140 mm Hg and/or diastolic BP greater than or equal to 90 mm Hg Prior to study entry, BP must be less than 180/110 mmHg for at least two weeks or treated hypertension AND 3. At least one of the following symptoms attributable to the Cushing s syndrome - Body weight increase or truncal obesity - Depression or treated depression or psychiatric disorder - Fatigue - Proximal muscle weakness - Hirsutism - Hypokalemia - Bruising - Violaceous striae - In men, gynecomastia or libido decrease - Impaired cognition or memory - Hyperpigmentation - Amenorrhea - Osteopenia or osteoporosis In addition, the following criteria should be met - Written informed consent to participate in the study - Female subjects should be sterilized, post-menopausal, sexually inactive or willing to use barrier methods of contraception throughout the study. - Subject willing to return to investigational site during the full course of the study - Age in the range of 18 to 75 years inclusive |
|
E.4 | Principal exclusion criteria |
- Evidence for Cushing s disease as judged by positive inferior petrosal sinus sampling or a lesion on pituitary MRI with positive CRH test - Suspected or known adrenocortical cancer or adenomas, as judged by ACTH values 10 pg/ml and adrenal mass - Subjects with cyclic Cushing s syndrome defined by at least 3 measurements of Urinary Free Cortisol over the previous two months without normal values. - Children age less than 18 and subject of more than 75 years of age - Pregnant or lactating women. A urinary pregnancy test will be performed in women of childbearing potential unless they have a history of menopause prior to Cushing s syndrome or hysterectomy - Life expectancy less than three months - Severe uncontrolled diabetes - Grade III or IV hypertension - Recent less than two weeks prior to inclusion initiation of corrective treatments for diabetes, hypertension or depression - Clinically significantly impaired cardiovascular function e.g. stage IV cardiac failure - Severe liver disease liver enzymes greater than or equal to 3 x the institutional upper limit of normal range - Severe renal impairment serum creatinine greater than or equal to 2.2 mg/dl or creatinine clearance 30 ml/min - Uncontrolled severe active infection - In women, known endometrial cancer, history of endometrial hyperplasia or vaginal bleeding of unknown cause - Recent less than two weeks prior to inclusion initiation of or significant change in dose of anti-tumor therapy - Treatment with approved or experimental steroidogenesis inhibitors, adrenolytic agents or somatostatin analogues within four weeks of admission - Plasma mitotane concentration 5 g/ml - Impaired mental capacity or markedly abnormal psychiatric evaluation that precludes informed consent - Body weight over 136 kg, which is the limit for the tables used in the scanning areas |
|
E.5 End points |
E.5.1 | Primary end point(s) |
A Assessment of primary efficacy data will be based on Blood pressure supine blood pressure and glucose tolerance fasting glucose in diabetes and 2-hour OGTT in glucose intolerance measured at visit P and additional visits M1 to M3 as applicable. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |